Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUSERPIN vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauwolfia alkaloid (reserpine) depletes catecholamines (norepinephrine, dopamine, serotonin) from sympathetic nerve endings and brain by irreversibly binding to vesicular monoamine transporter (VMAT). This results in reduced sympathetic outflow, decreased heart rate, and vasodilation.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Hypertension,Psychotic disorders (off-label),Schizophrenia (off-label)
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
Initial: 0.1-0.25 mg orally once daily; increase gradually to 0.5-1 mg per day in 2 divided doses. Maximum: 3 mg/day.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal elimination half-life: 4-8 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Hepatic via CYP2D6; undergoes extensive first-pass metabolism; metabolites excreted in urine and feces.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (15-20%)
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
80-90% bound primarily to albumin
~10-20% bound to plasma proteins (primarily albumin).
1.0-2.0 L/kg; clinical meaning: indicates extensive tissue distribution, including CNS.
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral: 80-90%; Intramuscular: 100%
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
GFR 30-50 m L/min: reduce dose by 25%. GFR 15-29 m L/min: reduce dose by 50%. GFR <15 m L/min: avoid use.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Not approved for pediatric use; safety and efficacy not established.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Initiate at 0.05 mg orally once daily; increase slowly. Maximum 1.5 mg/day. Monitor for orthostatic hypotension and sedation.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
No FDA black box warning.
None
May cause severe depression with high risk of suicide,Electroconvulsive therapy (ECT) should be discontinued at least 7 days prior,Use cautiously in patients with history of peptic ulcer disease (increased gastric acid secretion),May precipitate biliary colic in patients with gallstones,Monitor for hypotension and bradycardia
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Hypersensitivity to rauwolfia alkaloids,History of mental depression (especially suicidal ideation),Active peptic ulcer,Ulcerative colitis,Electroconvulsive therapy (within 7 days),Pheochromocytoma,Concomitant use with MAO inhibitors
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, pickled fish, ferments) as RAUSERPIN may potentiate their pressor effects, leading to hypertensive crisis. Limit alcohol intake due to increased risk of hypotension and sedation.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
Rauserpin (reserpine) crosses the placenta. First trimester: Increased risk of congenital malformations including skeletal and cardiovascular anomalies based on animal studies; human data limited but avoid use. Second and third trimesters: Fetal bradycardia, hypothermia, and respiratory depression due to catecholamine depletion. Neonatal withdrawal: Lethargy, nasal congestion, and poor feeding. Avoid use throughout pregnancy.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Reserpine is excreted into breast milk with an M/P ratio of approximately 1.0. Potential for significant effects in the nursing infant including bradycardia, sedation, and gastrointestinal disturbances. Use is contraindicated during breastfeeding.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
Plasma volume expansion in pregnancy may reduce reserpine concentrations. No established dose adjustment guidelines; clinical response monitoring is recommended. Avoid due to fetal risks. If unavoidable, use lowest effective dose and frequent monitoring.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
RAUSERPIN (rauwolfia alkaloid) is an antihypertensive that depletes catecholamines from postganglionic sympathetic nerve endings. Onset of effect is slow (weeks), and it may cause significant bradycardia and sedation. Avoid in patients with history of depression, peptic ulcer disease, or pheochromocytoma. Use with caution in patients receiving MAOIs or other antihypertensives due to additive effects.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take this medication exactly as prescribed, usually once daily at the same time each day.,It may take several weeks to see the full benefit; do not stop abruptly as this may cause rapid increase in blood pressure.,This drug may cause drowsiness, dizziness, or nasal congestion; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and sedatives as they may worsen drowsiness.,Contact your doctor if you experience depression, slow heart rate, fainting, or signs of stomach ulcer (e.g., black stools, stomach pain).
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUSERPIN vs ALDOMET, answered by our medical review team.
RAUSERPIN is a Antihypertensive that works by Rauwolfia alkaloid (reserpine) depletes catecholamines (norepinephrine, dopamine, serotonin) from sympathetic nerve endings and brain by irreversibly binding to vesicular monoamine transporter (VMAT). This results in reduced sympathetic outflow, decreased heart rate, and vasodilation.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUSERPIN and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUSERPIN is: Initial: 0.1-0.25 mg orally once daily; increase gradually to 0.5-1 mg per day in 2 divided doses. Maximum: 3 mg/day.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUSERPIN and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUSERPIN is classified as Category C. Rauserpin (reserpine) crosses the placenta. First trimester: Increased risk of congenital malformations including skeletal and cardiovascular anomalies based on animal studies; hum. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.